The world’s first-ever antibiotic cocktail to treat a life-threatening bacterial infection can also be made from a plant. 

The cocktail of erythromycin and erythropoietin from the plant Bacillus subtilis was developed by scientists at the University of Bristol.

It is the first such antibiotic cocktail that can be made in the lab, according to the study, published in the journal Nature Communications.

The cocktail, called erythrocyte-derived erytropharmaceuticals, was developed with the help of an international team led by Dr. Daniela R. Halle, the first author of the paper and a professor in the department of microbiology and immunology at the university.

Halle is now a postdoctoral researcher in the group’s laboratory.

The research team included scientists from Bristol and the University College London, as well as the University and Royal College of Surgeons of London.

Hale said that this type of antibiotic cocktail could be used to treat people who are currently at risk of dying from antibiotic-resistant bacterial infections.

“We think that this combination will be the best one we have ever created to help people who may be at high risk of developing severe acute bacterial infections and severe chronic infections,” she said.

“It’s really exciting because it’s not just about the antibiotics that are being made, but the whole package, the bioengineering that goes into making these therapeutics.”

The researchers have created a cocktail of the two antibiotics.

The bacterial part of the cocktail is made from the antibiotic erythyrolyticum  and the plant-derived antibiotic epylactis.

The antibiotic is a bacterium that is found in bacteria such as the erythemoidia fungus that causes stomach ulcers.

Epylactus, or erytha, is a more powerful form of erylacridine, a bactericidal compound used in antibiotics.

The drug is commonly used to control parasitic infections in humans and is used to protect the intestines from infection.

It also works in the gut and in the lungs, which are important sites for many diseases.

The bioengineering part of the treatment is made of the plant eryythromycin, which is the antibiotic’s main active ingredient.

It binds to the bacteria’s receptors in the gastrointestinal tract and stimulates the production of a compound called epidemic cytochrome P450.

The drug’s active ingredient is erytriamycin, also known as erytetracycline, which binds to its receptor in the lung.

Epidemic erytracyclines, also called cytochromic compounds, have been used in many medicines to treat many diseases, including cancer and heart disease. 

“We thought we could make a good cocktail that we could take in our stomach and make it into a drug that would have a very low chance of causing a serious infection, and then the antibiotic could be made into a much stronger drug,” said Halle.

The team has been able to make a cocktail that works in animals and humans, which means the cocktail will likely work for people with mild to moderate illnesses, such as chronic fatigue syndrome and allergies.

The researchers said that their cocktail can be used in animals as well, although the researchers have not yet tested the cocktail in humans.

“Our current experiments are not showing the drug works as well in humans as we expect, but it could,” said Rohit Ramakrishnan, one of the lead authors of the study and a post-doctoral researcher at the Bristol lab.

“The antibiotic cocktail is a very novel and powerful tool for treating people with severe bacterial infections.”